Prognostic value of [18F]FDG PET/CT in follicular lymphoma

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2026-03-01 Epub Date: 2025-09-12 DOI:10.1016/j.remnie.2025.500229

A. Díaz Silván , D. Cabello García , L.F. Otón Sánchez

{"title":"Prognostic value of [18F]FDG PET/CT in follicular lymphoma","authors":"A. Díaz Silván , D. Cabello García , L.F. Otón Sánchez","doi":"10.1016/j.remnie.2025.500229","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prognostic value of [<sup>18</sup>F]FDG PET/CT in follicular lymphoma (FL) patients in our routine clinical practice.</div></div><div><h3>Material and methods</h3><div>Retrospective study of FL patients assessed with PET/CT in our centre from 01/06/2008 to 01/06/2020. This study aimed to investigate the prognostic value of quantitative parameters (MTV, TLG, ΔSUV max) and qualitative criteria (Lugano classification), and its relationships with progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>Among patients with available staging PET/CT, the 5-year OS was 90.4% for those with lower MTV and 89.7% for those with higher MTV (p = 0.3). The PFS was 77.6% for those with lower MTV and 53.2% for those with higher MTV (p = 0.001). TLG yielded statistically similar results.</div><div>A ΔSUV max ≥ 66% was associated with higher OS and PFS at 5 years, at both interim and final PET/CT studies (iPET and fPET). The 5-year OS for patients with complete metabolic response was 86.3% in iPET and 89.0% in fPET, compared to 84.1% and 79.0%, respectively, for those positive in iPET (p = 0.3) and fPET (p = 0.1). The 5-year PFS for patients with complete metabolic response was 76.9% in iPET and 73.1% in fPET, compared to 58.7% and 62.2%, respectively, for those positive in iPET (p = 0.04) and fPET (p = 0.09).</div></div><div><h3>Conclusions</h3><div>PET/CT is valuable as a prognostic factor in FL, both during staging (providing parameters with independent prognostic value such as MTV and TLG) and during and after treatment (as it correlates with survival).</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 2","pages":"Article 500229"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de medicina nuclear e imagen molecular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253808925001302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To determine the prognostic value of [¹⁸F]FDG PET/CT in follicular lymphoma (FL) patients in our routine clinical practice.

Material and methods

Retrospective study of FL patients assessed with PET/CT in our centre from 01/06/2008 to 01/06/2020. This study aimed to investigate the prognostic value of quantitative parameters (MTV, TLG, ΔSUV max) and qualitative criteria (Lugano classification), and its relationships with progression-free survival (PFS) and overall survival (OS).

Results

Among patients with available staging PET/CT, the 5-year OS was 90.4% for those with lower MTV and 89.7% for those with higher MTV (p = 0.3). The PFS was 77.6% for those with lower MTV and 53.2% for those with higher MTV (p = 0.001). TLG yielded statistically similar results.

A ΔSUV max ≥ 66% was associated with higher OS and PFS at 5 years, at both interim and final PET/CT studies (iPET and fPET). The 5-year OS for patients with complete metabolic response was 86.3% in iPET and 89.0% in fPET, compared to 84.1% and 79.0%, respectively, for those positive in iPET (p = 0.3) and fPET (p = 0.1). The 5-year PFS for patients with complete metabolic response was 76.9% in iPET and 73.1% in fPET, compared to 58.7% and 62.2%, respectively, for those positive in iPET (p = 0.04) and fPET (p = 0.09).

Conclusions

PET/CT is valuable as a prognostic factor in FL, both during staging (providing parameters with independent prognostic value such as MTV and TLG) and during and after treatment (as it correlates with survival).

查看原文本刊更多论文

[18F]FDG PET/CT对滤泡性淋巴瘤的预后价值。

目的：探讨[18F]FDG PET/CT对滤泡性淋巴瘤（follicular lymphoma， FL）患者预后的临床价值。材料与方法：回顾性研究本中心2008年6月1日至2020年6月1日经PET/CT检查的FL患者。本研究旨在探讨定量参数（MTV、TLG、ΔSUV max）和定性标准（Lugano分类）的预后价值，及其与无进展生存期（PFS）和总生存期（OS）的关系。结果：在可分期的PET/CT患者中，MTV低组5年OS为90.4%，MTV高组为89.7% （p = 0.3）。低MTV组的PFS为77.6%，高MTV组为53.2% （p = 0.001）。TLG产生了统计上相似的结果。在中期和最终PET/CT研究（iPET和fPET）中，ΔSUV max≥66%与5年的OS和PFS较高相关。iPET和fPET完全代谢应答患者的5年OS分别为86.3%和89.0%，而iPET和fPET阳性患者的5年OS分别为84.1%和79.0% （p = 0.3）和p = 0.1)。iPET和fPET完全代谢反应患者的5年PFS分别为76.9%和73.1%，而iPET和fPET阳性患者的5年PFS分别为58.7%和62.2% （p = 0.04）和p = 0.09。结论：PET/CT作为FL的预后因素是有价值的，无论是在分期期间（提供具有独立预后价值的参数，如MTV和TLG），还是在治疗期间和治疗后（因为它与生存相关）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista espanola de medicina nuclear e imagen molecular

自引率

0.00%

发文量